Actively Recruiting
First in Human Study of AZD9592 in Solid Tumors
Led by AstraZeneca · Updated on 2026-05-11
403
Participants Needed
51
Research Sites
293 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
CONDITIONS
Official Title
First in Human Study of AZD9592 in Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- ECOG Performance Status of 0 or 1
- Life expectancy of at least 12 weeks
- Measurable disease according to RECIST v1.1
- Adequate organ and bone marrow function as defined in the study protocol
- For Module 1: Confirmed metastatic or locally advanced EGFR mutant or wild-type non-small cell lung cancer, recurrent or metastatic head and neck squamous cell carcinoma of the oral cavity, or metastatic colorectal cancer
- For Module 2: Confirmed metastatic EGFR mutant non-small cell lung cancer
- For Module 3: Confirmed metastatic colorectal cancer
You will not qualify if you...
- History of non-infectious interstitial lung disease or pneumonitis requiring steroids, current interstitial lung disease or pneumonitis, or suspected cases not ruled out by imaging
- Spinal cord compression or history of leptomeningeal carcinomatosis
- Active infections including tuberculosis, hepatitis B, hepatitis C, or HIV
- Brain metastases unless treated (prior treatment required for Module 1), asymptomatic, stable, and not needing continuous corticosteroids above 10 mg prednisone daily or equivalent for at least 4 weeks before treatment
- Cardiac conditions as defined in the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 51 locations
1
Research Site
Duarte, California, United States, 91010
Actively Recruiting
2
Research Site
Irvine, California, United States, 92618
Withdrawn
3
Research Site
North Haven, Connecticut, United States, 06473
Actively Recruiting
4
Research Site
Washington D.C., District of Columbia, United States, 20016
Actively Recruiting
5
Research Site
Coral Gables, Florida, United States, 33146
Not Yet Recruiting
6
Research Site
Chicago, Illinois, United States, 60637
Actively Recruiting
7
Research Site
Baltimore, Maryland, United States, 21224
Actively Recruiting
8
Research Site
Baltimore, Maryland, United States, 21231
Actively Recruiting
9
Research Site
Milford, Massachusetts, United States, 01757
Actively Recruiting
10
Research Site
Mineola, New York, United States, 11501
Actively Recruiting
11
Research Site
New York, New York, United States, 10016
Actively Recruiting
12
Research Site
New York, New York, United States, 10021
Actively Recruiting
13
Research Site
New York, New York, United States, 10029
Actively Recruiting
14
Research Site
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
15
Research Site
Providence, Rhode Island, United States, 02903
Actively Recruiting
16
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
17
Research Site
Fairfax, Virginia, United States, 22031
Actively Recruiting
18
Research Site
Kogarah, Australia, 2217
Actively Recruiting
19
Research Site
Melbourne, Australia, 3000
Actively Recruiting
20
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
21
Research Site
Toronto, Ontario, Canada, M5G 1X6
Actively Recruiting
22
Research Site
Beijing, China, 100142
Actively Recruiting
23
Research Site
Beijing, China, 100142
Not Yet Recruiting
24
Research Site
Chongqing, China, 400030
Actively Recruiting
25
Research Site
Guangzhou, China, 510100
Actively Recruiting
26
Research Site
Harbin, China, 150049
Not Yet Recruiting
27
Research Site
Wuhan, China, 430022
Actively Recruiting
28
Research Site
Marseille, France, 13385
Actively Recruiting
29
Research Site
Rennes, France, 35000
Actively Recruiting
30
Research Site
Villejuif, France, 94805
Actively Recruiting
31
Research Site
Milan, Italy, 20162
Actively Recruiting
32
Research Site
Orbassano, Italy, 10043
Actively Recruiting
33
Research Site
Rozzano, Italy, 20089
Actively Recruiting
34
Research Site
Verona, Italy, 37134
Actively Recruiting
35
Research Site
Chūōku, Japan, 104-0045
Actively Recruiting
36
Research Site
Kashiwa, Japan, 277-8577
Actively Recruiting
37
Research Site
Kōtoku, Japan, 135-8550
Actively Recruiting
38
Research Site
Osaka, Japan, 541-8567
Actively Recruiting
39
Research Site
Kuala Lumpur, Malaysia, 59100
Actively Recruiting
40
Research Site
Kuching, Malaysia, 93586
Actively Recruiting
41
Research Site
Seoul, South Korea, 03080
Actively Recruiting
42
Research Site
Seoul, South Korea, 03722
Actively Recruiting
43
Research Site
Seoul, South Korea, 05505
Actively Recruiting
44
Research Site
Seoul, South Korea, 06351
Actively Recruiting
45
Research Site
Barcelona, Spain, 8035
Actively Recruiting
46
Research Site
Madrid, Spain, 28040
Actively Recruiting
47
Research Site
Seville, Spain, 41013
Actively Recruiting
48
Research Site
Taichung, Taiwan, 40705
Actively Recruiting
49
Research Site
Taipei, Taiwan, 10002
Actively Recruiting
50
Research Site
Taipei, Taiwan, 11217
Actively Recruiting
51
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here